Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DR26FMDX7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,318.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector units. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of November 19, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) designated SPE2DR, which was established under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative on November 13, 2025.
The PPV-G GEN V represents a $30.3 billion acquisition strategy through which the DLA establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's IDC carries a $499.999 billion ceiling value and extends through December 31, 2036, structured with a 30-month base period and three 30-month option periods. As a critical pharmaceutical supplier within the federal military medical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance across diverse product categories and delivery orders, positioning it to fulfill the specialized pharmaceutical requirements of DoD healthcare operations globally. No subcontractors have been identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FMDX7?
SPE2DR26FMDX7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FMDX7 worth?
The government has obligated $19,318 on SPE2DR26FMDX7.
Is contract SPE2DR26FMDX7 an order under another contract?
Yes. SPE2DR26FMDX7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDX7 competed?
The extent of competition for SPE2DR26FMDX7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award